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The anti-inflammatory protein annexin A1 (ANXA1) has been associated with
cancer progression and metastasis, suggesting its role in regulating tumor cell
proliferation. We investigated the mechanism of ANXA1 interaction with formylated
peptide receptor 2 (FPR2/ALX) in control, peritumoral and tumor larynx tissue
samples from 20 patients, to quantitate the neutrophils and mast cells, and to
evaluate the protein expression and co-localization of ANXA1/FPR2 in these
inflammatory cells and laryngeal squamous cells by immunocytochemistry. In
addition, we performed in vitro experiments to further investigate the functional role
of ANXA1/FPR2 in the proliferation and metastasis of Hep-2 cells, a cell line from
larynx epidermoid carcinoma, after treatment with ANXA12–26 (annexin A1 N-
terminal-derived peptide), Boc2 (antagonist of FPR) and/or dexamethasone. Under
these treatments, the level of Hep-2 cell proliferation, pro-inflammatory cytokines,
ANXA1/FPR2 co-localization, and the prostaglandin signalling were analyzed using
ELISA, immunocytochemistry and real-time PCR. An influx of neutrophils and
degranulated mast cells was detected in tumor samples. In these inflammatory cells
of peritumoral and tumor samples, ANXA1/FPR2 expression was markedly
exacerbated, however, in laryngeal carcinoma cells, this expression was down-
regulated. ANXA12–26 treatment reduced the proliferation of the Hep-2 cells, an
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effect that was blocked by Boc2, and up-regulated ANXA1/FPR2 expression.
ANXA12–26 treatment also reduced the levels of pro-inflammatory cytokines and
affected the expression of metalloproteinases and EP receptors, which are involved
in the prostaglandin signalling. Overall, this study identified potential roles for the
molecular mechanism of the ANXA1/FPR2 interaction in laryngeal cancer, including
its relationship with the prostaglandin pathway, providing promising starting points
for future research. ANXA1 may contribute to the regulation of tumor growth and
metastasis through paracrine mechanisms that are mediated by FPR2/ALX. These
data may lead to new biological targets for therapeutic intervention in human
laryngeal cancer.
Introduction
Laryngeal cancer is one of the most common types of head and neck tumors that
has a high mortality rate and a poor prognosis [1]. More than 12,500 new cases of
laryngeal cancer are diagnosed annually and 3,560 annual deaths occur [2]. The
development of better treatment as well as better diagnostic and preventive
approaches requires an improved understanding of the complex process of
laryngeal tumorigenesis.
Only 5% to 10% of all cancers are caused by the inheritance of mutated genes,
whereas the remaining 90% to 95% of cases have been linked to genetic and
epigenetic alterations caused by lifestyle and environmental factors, such as
cigarette smoking and alcohol use [3, 4]. It is now well recognized that
inflammation is a risk factor for most types of cancer, including laryngeal
carcinomas [5, 6]. Chronic inflammation has been linked to various steps involved
in tumorigenesis, including cellular transformation, promotion, proliferation,
invasion, angiogenesis, and metastasis [7, 8]. Hanahan and Weinberg, in their
recent review [9], recognized inflammation as a new hallmark of cancer that
promotes multiple tumor features.
Inflammatory cells secrete numerous cytokines, chemokines and growth factors
that can stimulate proliferation, inhibit apoptosis, induce morphogenesis and
generate DNA-damaging reactive oxygen species [7], facilitating genomic
instability [10]. Furthermore, these cells synthesize vascular endothelial growth
factor (VEGF), angiopoetin, metalloproteinases and other proteins that can
stimulate vascular endothelial cell mitosis and extracellular matrix remodeling
[11]. Therefore, inflammation generates not only changes in the microenviron-
ment to promote cancer but also changes that stimulate neoplastic progression.
It has been demonstrated that mast cells and neutrophils can be recruited by
tumor cells. Increased numbers of mast cells have been reported in mammary [12]
and lung carcinomas [13], among other tumors. Experimental evidence has
indicated that activated mast cells release angiogenic growth factors and
regulators, prostaglandin, metalloproteinases and cytokines [14], and may play a
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dual role in promoting or inhibiting tumor growth depending on the local
stromal conditions [15, 16]. Of the cell types residing in the tumor microenvir-
onment, tumor-associated neutrophils (TANs) have received little attention [17].
Although there is evidence suggesting a role for neutrophils in enhanced disease
progression in specific human tumors, the relationship between neutrophil
infiltration and prognosis in human cancer has not been systematically
investigated [18]. The role of neutrophils in tumor progression remains
controversial [19] largely because these cells have both tumor-promoting and
tumoricidal functions depending on the presence of transforming growth factor
beta (TGF-b) [20, 21].
From these studies, it is clear that various inflammatory mediators are
differentially expressed in several cancers and can stimulate disease progression
[22]. Thus, agents that suppress these inflammatory mediators represent potential
targets for the treatment of cancer. The anti-inflammatory protein annexin 1
(ANXA1), a 37-kDa member of the annexin superfamily, is a steroid-regulated
protein that is implicated in mediating some of the beneficial activities of
glucocorticoids [23], including the regulation of cell proliferation [24],
differentiation [25] and metastasis [26].
Dysregulation of ANXA1 has been reported in multiple neoplasms, suggesting
that this protein may play important roles in tumor development and progression
[27]. ANXA1 is overexpressed in breast cancer [28] and hepatocellular carcinoma
[29] but is markedly down-regulated in esophageal [30, 31] and head and neck
carcinomas [32]. However, the molecular mechanisms by which ANXA1
modulates cellular responses have not been fully determined.
Advances in this area have shown a functional link between the anti-
inflammatory properties of ANXA1 and receptor for formyl-Met-Leu-Phe (fMLP)
FPR [33], a specific class of G protein-coupled 7-transmembrane receptors [34].
In humans, three family members have been identified, FPR1, FPR2/ALX (FPRL1)
and FPR3 (FPRL2) [35]. Some of the effects of exogenous ANXA1 can be
attenuated by Boc2, an antagonist of both FPR1 and FPR2 [33]. Recently, it has
been shown that the ANXA1 N-terminal peptide, ANXA12–26, promotes the
migration of WS1 human skin fibroblasts [36], and the invasiveness of SKCO-15
colorectal adenocarcinoma cells [24] through interaction with FPRs. However, no
data are available regarding the role of ANXA1 and FPRs in laryngeal squamous
cell carcinoma.
Several signaling pathways mediate inflammation-associated tumorigenesis. For
example, cyclooxygenase-2 (COX-2), an enzyme involved in the conversion of
arachidonic acid to prostaglandins, is considered to play important roles in cancer
development by modulating cell proliferation and other important biological
processes via their metabolites, G protein-coupled receptors and downstream
effectors [37]. COX-2 is up-regulated in several malignancies [38–40], including
head and neck carcinomas [41]. Actually, Abrahao et al. (2010) have shown that
the pro-inflammatory COX-2 metabolite prostaglandin E2 and its EP3 receptor
can activate head and neck carcinoma cells to proliferate and is a potential target
for preventive approaches. Considering that glucocorticoids are highly effective
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inhibitors of COX-2 expression [42], the steroid-regulated protein annexin A1,
which is implicated in mediating some of the activities of glucocorticoids, may
also be involved in the inflammatory network linked to COX-2.
Given the potential role for ANXA1 in multiple neoplasms such as the
regulation of cell proliferation, differentiation and metastasis, we focused on the
molecular mechanisms by which ANXA1 modulates these cellular responses. In
this report, we showed that ANXA1 protein is down-regulated in human laryngeal
carcinoma and can regulate tumor growth in a paracrine manner that is mediated
by the receptor FPR2/ALX. This investigation demonstrates the potential
significance of this ANXA1/FPR2 interaction in tumorigenesis. Overall, this study
identified potential roles for the molecular mechanism of this protein interaction
in laryngeal cancer, including its relationship with the prostaglandin pathway,
providing evidence for the potential of ANXA1 as a therapeutic target and
promising starting points for future research.
Materials and Methods
Tissue Samples
Human invasive laryngeal cancer tissues were obtained from 20 patients with
laryngeal squamous cell carcinoma who were treated at the Hospital de Base in
Sa˜o Jose´ do Rio Preto, Brazil. The patients were male, alcoholic smokers, their age
ranged from 50 to 80 years, and none of them had received radiotherapy or
chemotherapy before intervention. In each patient (n520), the surgical tumor
samples were collected from the center of the laryngeal tumor, the peritumoral
samples were collected from the tumor periphery, and the control samples were
collected from the region free of tumor cells. Because of the high heterogeneity of
laryngeal carcinoma, the tumor tissues were dissected and reviewed by a senior
pathologist and were characterized as moderately differentiated, invasive
carcinomas. These tissue samples were used in a previous study that was
conducted in our laboratory, and the number of patients was sufficient to obtain
statistically significant data [32]. The study protocol was approved by the
Committee of Ethics in Research of the Federal University of Sa˜o Paulo, School of
Medicine, Brazil (CEP-0300/08), and written informed consent was obtained from
all of the patients involved.
Cell Culture
The Hep-2 cell line, which was originally established from an epidermoid
carcinoma of the larynx, was used in the present study (ATCC, Rockville,
Maryland, USA). Cell line authentication was performed using the AmpFLSTR
Identifiler PCR Amplification Kit (Life Technologies) at the Special Techniques
Laboratory, Hospital Israelita Albert Einstein (LATE -HIAE), Sao Paulo. We
found 100% identity of our cell line compared with the American Type Culture
Collection (ATCC) database. The cells were seeded at a density of 26106 cells in a
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75-cm2 culture flask (Corning, NY, USA) and incubated in MEM-Earle medium
(Cultilab, Campinas, SP, Brazil), pH 7.5, supplemented with 20% fetal calf serum
(Cultilab), 1% non-essential amino acids, and 0.1% antibiotic/antimycotic
solution (Invitrogen Corporation, Carlsbad, CA, USA), at 37 C˚ in a humid
atmosphere of 5% CO2 [43].
Drug Treatment
For the pharmacological experiments, Hep-2 cells were seeded as previously described.
Twenty-four hours later, after the cells had already adhered, they were incubated in
serum-free medium to synchronize the cell cycle. After an additional 24 hours, the
medium was replaced with complete growth medium containing the following: (a)
1 mM of ANXA12–26 peptide (Ac-AMVSEFLKQAWFIENEEQEYVQTVK)
(Invitrogen); (b) 1 mM of ANXA12–26 peptide and 10 mM Boc2, a nonselective FPR
antagonist (N-t-BOC-MET-LEU-PHE) (MP Biomedicals, Aurora, OH); (c)
0.01 mM dexamethasone (a glucocorticoid; Sigma-Aldrich, St. Louis, MO, USA);
(d) 0.01 mM dexamethasone and 10 mM Boc2; or (e) 10 mM Boc2 alone. The drugs
were first dissolved in small amounts of dimethyl sulfoxide (DMSO) and then
diluted in medium (the final concentration of DMSO never exceeded 1%). The
concentrations of the drugs were selected based on preliminary experiments and
literature data [32, 44]. The control cells were treated with complete medium with
the same concentration of DMSO used to dilute the drugs. Every 2 days, the
medium was replaced with fresh medium containing the drugs at the same dose; the
cell morphology was observed every day [43]. After 6, 24, 48, 72 and 96 hours,
control and treated cells were harvested and counted using the Countess Automated
Cell Counter (Invitrogen).
Fixation, Processing, and Embedding for Light and Electron
Microscopy
Laryngeal samples and Hep-2 cells were fixed in 4% paraformaldehyde, 0.5%
glutaraldehyde, and 0.1 mol/L sodium cacodylate buffer (pH 7.4) for 24 hours at
4 C˚, washed in sodium cacodylate, dehydrated through graded percentages of
ethanol, and embedded in LRGold (London Resin Co., Reading, UK). For
histopathological and morphological analyses, tissue sections (0.5-mm thick) were
cut on an ultramicrotome (Reichert Ultracut; Leica, Austria), stained with 1%
toluidine blue in 1% borax solution (TAAB Laboratories, Aldermaston, UK) and
examined using an AXIOSKOP 2-Mot Plus ZEISS microscope (Carl Zeiss, Jena,
Germany). For electron microscopy, sections (,90 nm) were cut on an
ultramicrotome and placed on nickel grids for immunogold labeling [45].
Immunogold Labeling of Post-embedded tissues
Immunocytochemistry reaction (double labeling) was used to detect the
expression and co-localization of ANXA1 and FPR2/ALX in mast cells,
neutrophils, and control and tumor cells from laryngeal tissues and Hep-2 cells.
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The Hep-2 cells were incubated with control medium, ANXA12–26 and
ANXA12–26+Boc2. After 48 hours, the culture was harvested, and the cells were
embedded in LRGold resin for immunocytochemical analysis. Ultrathin sections
of laryngeal tissues and Hep-2 cells were incubated in a step-by-step manner using
the following reagents and/or conditions at room temperature: 1) distilled water;
2) 0.1 mol/L phosphate buffer containing 1% egg albumin (PBEA); 3) 0.1 mol/L
PBS containing 5% PBEA for 30 minutes; 4) sheep polyclonal antibody LCPS1,
raised against the N-terminal segment of ANXA1 (1:500 in PBEA) and rabbit
polyclonal antibody FPR2/ALX (Abcam, Cambridge, UK) (1:500 in PBEA) for
2 hours; normal sheep and rabbit sera were used as the control (1:500); 5) three
washes in PBEA containing 0.01% Tween 20; 6), donkey anti-sheep IgG (Fc
fragment-specific) antibody (1:100 in PBEA) conjugated to 15-nm colloidal gold
(British Biocell, UK) was added to detect ANXA1, and goat anti-rabbit IgG (Fc
fragment-specific) antibody (1:100 in PBEA) conjugated to 10-nm colloidal gold
(British Biocell) was added to detect FPR2/ALX). After 1 hour, the sections were
washed in PBEA containing 0.01% Tween 20, and then in distilled water [46].
Sections were stained with uranyl acetate and lead citrate before examination on a
ZEISS LEO 906 electron microscope (Carl Zeiss, Jena, Germany).
Multiplex Assays
To quantify the pro-inflammatory cytokines interleukins 6 (IL-6) and IL-8 as well
as monocyte chemotactic protein-1 (MCP-1), in the Hep-2 cell culture
supernatants, we used the multiplex instrument LUMINEX xMAP MAGPIX
(Millipore Corporation, Billerica, MA, USA). The cells were incubated with
control medium, ANXA12–26, ANXA12–26+Boc2, Dexa, Dexa+Boc2 or Boc2. After
48 hours of treatment, the culture supernatants were removed, centrifuged and
stored at 220 C˚. Antibody beads, controls, wash buffer, serum matrix and
standards were prepared following the manufacturer’s instructions (MILLIPLEX
HCYTOMAG-60K kit). Next, 200 mL of wash buffer was added to each well of a
magnetic 96-well plate and mixed on a shaker for 10 min. The wash buffer was
decanted, and 25 ml of standards, controls and samples were added to the wells.
Next, 25 ml of assay buffer was added to the samples, and 25 ml of serum matrix
was added to the standards. Finally, 25 ml of magnetic beads (coated with a
specific capture antibody) was added to all wells and incubated overnight at 4 C˚
on a shaker. The next day, the plate was washed with wash buffer and incubated
with 25 ml of detection antibodies for 1 hour on a shaker. Next, 25 mL of
streptavidin-phycoerythrin was added to each well and incubated for 30 minutes
on a shaker. The plate was washed and incubated with 150 ml of drive fluid for
5 minutes on a shaker. Finally, the plate was analyzed using MAGPIX with
xPONENT software [47].
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Real-time PCR
The Hep-2 cells were incubated with control medium, ANXA12–26 or ANXA12–
26+Boc2 and harvested after 48 hours. Total RNA was extracted using TRIzol
Reagent (Invitrogen) according to the manufacturer’s protocol. The genomic
DNA was removed by DNase treatment according to the manufacturer’s
description (Promega). Aliquots (2 mg) of total RNA from control and treated
cells were used for double-stranded cDNA synthesis using a High Capacity cDNA
Archive kit (Applied Biosystems) according to the manufacturer’s instructions.
Four differentially expressed genes (EP3 or PTGER3, EP4 or PTGER4, MMP2 and
MMP9) were selected for quantitative real-time PCR experiments according to
their direct or indirect involvement in inflammatory and metastatic processes
based on the Gene Ontology database (http://www.geneonthology.org/). Real-
time PCR was performed in triplicate using a 7500 Fast Real-Time PCR System
(Applied Biosystems). The reaction mixture consisted of a 20-ml total volume
solution containing 10 ml of Power SYBR Green PCR Master Mix (Applied
Biosystems), a 1 mM solution of each primer and 20 ng of cDNA. The PCR
conditions were 50 C˚ for 2 min and 95 C˚ for 10 min, followed by 40 cycles of
95 C˚ for 15 s and 60 C˚ for 1 min. Melting curve analysis was conducted for each
gene to check the specificity and identity of the RT-PCR products. For each
primer set, the real-time PCR efficiencies (E) were measured in triplicate on serial
dilutions of the same cDNA sample using the formula E5[10(21/slope)]. The
resulting values ranged from 1.96 to 2.02. Each transcript level was normalized to
the internal standard GAPDH, and the values were Log2-transformed (y-axis) so
that all of the values below 21 indicated down-regulation in gene expression,
while values above 1 represented up-regulation compared with control cells [43].
Statistical Analysis
The values concerning the quantification of mast cells and neutrophils of the in
vivo tissue samples were expressed as the mean ¡ SEM of the number of cells per
mm2 in three sections of 0.5 mm (leaving a space of 40 mm between each section)
for each patient (n520 patients).
Hep-2 cells were counted using the Countess Automated Cell Counter
(Invitrogen). The concentration of the cytokines was determined using MAGPIX
Xponent software (Millipore Corporation). The in vitro analyses were repeated a
minimum of three times.
The ultrastructural and immunocytochemistry expression of ANXA1 and FPR2
was determined using ten cells for each group investigated. The area of each cell
compartment was determined using Axiovision imaging software (Zeiss). In the
nucleus and cytoplasm, the density of colloidal gold particles was calculated as the
mean ¡ SEM of the number of particles per mm2. In the plasma membrane, the
density of colloidal gold particles was calculated as the mean ¡ SEM of the
number of particles per mm.
The significant differences between the means were determined using analysis
of variance. This test was followed by the Bonferroni post-hoc test on select
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experimental groups using Graph-Pad Prism 4.0 (Graph-Pad, San Diego, CA,
USA). A probability value less than 0.05 was considered to be statistically
significant.
Results
The Presence of Degranulated Mast Cells and an Influx of
Neutrophils Indicates Inflammation in the Tumor Microenvironment
To verify the interaction of inflammatory cells with laryngeal tumor cells, we
performed histological analyses in larynx tissue samples to quantify mast cells and
neutrophils, important cells of the inflammatory response. In control samples, we
observed intact mast cells with metachromatic granules in close vicinity to blood
vessels (Fig. 1A). In the peritumoral and tumor stroma, we verified the presence of
degranulated mast cells (Fig. 1, B and C). In addition, we observed neutrophils
that had transmigrated into tumor sections (Fig. 1D).
Statistical analysis showed that there were high numbers of mast cells in the
control sections of the larynx and significantly fewer mast cells in the peritumoral
and tumor regions (P,0.001; Fig. 1E). Furthermore, intact mast cells were more
abundant in control samples and significantly lower in peritumoral and tumor
sections (P,0.001; Fig. 1F). Using quantitative analysis of the neutrophils, we
verified that there was a significant increase in these cells in the tumor tissues
(P,0.001) compared with control and peritumoral tissues (Fig. 1G). Examination
of the neutrophils in control and peritumoral sections showed that most of these
cells were localized in the blood vessels (Fig. 1H). By contrast, in the tumor
samples, we observed a significant number of transmigrated neutrophils in the
stroma (P,0.001 compared with control and peritumoral samples) (Fig. 1H).
Up-Regulation of ANXA1/FPR2 in the Inflammatory Cells of Human
Laryngeal Tumors
Ultrastructural immunocytochemistry showed for the first time the expression of
FPR2/ALX and its co-localization with ANXA1 in mast cells (Fig. 2, A–C). The
mast cells and neutrophils displayed ANXA1 and FPR2/ALX immunoreactivity in
the plasma membrane, cytoplasm and nucleus (Fig. 2, A–F). No immunogold
labeling was detected in sections that were incubated with nonimmune serum
(data not shown). In these inflammatory cells, we verified a significant up-
regulation of ANXA1 and FPR2/ALX expression in the peritumoral and tumor
samples compared with the corresponding control tissues (Fig. 2, G–L).
Quantitative analysis revealed that there is higher expression of ANXA1 and its
receptor in the cytoplasm and nucleus compared with that in the plasma
membrane (Fig. 2, G–L). Co-localization of ANXA1 and FPR2/ALX was observed
in the plasma membrane, cytoplasm and nucleus of mast cells and neutrophils
(Fig. 2, G–L); however there was significant difference only in plasma membrane
of peritumoral neutrophils (Fig. 2J).
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Fig. 1. Influx of inflammatory cells in tumor samples from human laryngeal. (A–D) Representative
images (original magnification, 663) of Toluidine Blue-stained tissue sections from laryngeal samples. (A)
Control laryngeal sample showing intact mast cells (curve arrows) near the blood vessels. Peritumoral (B) and
tumor (C) samples with degranulated mast cells (open curve arrows). (D) Tumor cells with mitotic activity
(open arrow) and inflammatory cells, as extravascular neutrophils (arrows). (E) Total number of mast cells. (F)
Intact and degranulated mast cells. (G) Total number of neutrophils. (H) Extra and intravascular neutrophils.
Data are expressed as the mean ¡ SEM of the cell number per mm2 (n520 patients per group). One-way
ANOVA followed by Bonferroni’s test revealed a significant difference among the groups. *** P,0.001 vs.
control, ### P,0.001 vs. peritumoral. Scale bars: 5 mm.
doi:10.1371/journal.pone.0111317.g001
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Fig. 2. Immunoreactivity to ANXA1 and FPR2/ALX in mast cells and neutrophils of laryngeal sections. Immunolabeling with 10-nm (FPR2/ALX) and
15-nm (ANXA1) colloidal gold particles. Mast cells (A–C) and neutrophils (D–F) showing subcellular localization of ANXA1 (arrows) and FPR2/ALX
(arrowheads), and co-localization (curve arrows) in the plasma membrane, cytoplasm and nucleus (N) of control, peritumoral and tumor tissues. Density of
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ANXA12–26 Inhibits FPR2/ALX Receptor-Mediated Proliferation of
Hep-2 Laryngeal Cancer Cells
Approximately 87% to 97% of the Hep-2 cells were viable under the experimental
conditions (control, ANXA12–26, ANXA12–26+Boc2, Dexa, Dexa+Boc2 and Boc2)
(S1 Figure). However, the growth curve of these cells showed significant
differences among the conditions studied (Fig. 3).
Treatment with the peptide ANXA12–26 significantly reduced the proliferation
of Hep-2 laryngeal cancer cells compared with the control cells (P,0.001 at 48
and 96 hours, and P,0.01 at 72 hours). Similar results were obtained after
treatment with Dexa and Dexa+Boc2 (S2 Figure). However, combination
treatment with ANXA12–26 and Boc2 (ANXA12–26+Boc) significantly augmented
cell growth compared with ANXA12–26-treated cells (P,0.01 at 48 and 72 hours,
and P,0.001 at 96 hours), demonstrating that Boc2 attenuated the antiproli-
ferative activity of ANXA12–26. Boc2-treated cells had a proliferative rate that was
similar to that of control cells (Fig. 3).
Loss of ANXA1/FPR2 Protein in Laryngeal Tumor Tissues and
Up-regulation after In Vitro Treatment with the ANXA12–26 Peptide
The epithelial cells of control, peritumoral and tumor laryngeal tissues displayed
immunoreactivity to ANXA1 and FPR2/ALX, as well as co-localizations of the
proteins, in the plasma membrane, cytoplasm and nucleus (Fig. 4, A–C). In the
peritumoral and tumor samples, we observed a marked reduction of ANXA1 and
FPR2/ALX protein expression compared with the corresponding control tissues (
Fig. 4, H and I). Quantitative analysis revealed that there was higher expression of
ANXA1 and its receptor in the cytoplasm and nucleus and lower expression in the
plasma membrane (Fig. 4, G–I). Differences in the degree of ANXA1/FPR2 co-
localization did not reach statistical significance among the laryngeal samples (
Fig. 4, G–I).
Hep-2 cells that were treated with ANXA12–26 or ANXA12–26 plus Boc2 showed
immunoreactivity for ANXA1 and FPR2/ALX (Fig. 4, D and E). Co-localization of
the two proteins was detected in the plasma membrane, cytoplasm and nucleus of
these cells but not in Boc2-treated cells (Fig. 4, D and E). No gold labeling was
detected in cells that were incubated with nonimmune serum (Fig. 4 F). ANXA1/
FPR2 expression was down-regulated in the plasma membrane but was increased
in the cytoplasm and nucleus of Hep-2 cells (Fig. 4, J–L). Treatment with
ANXA12–26 displayed up-regulation of ANXA1 and FPR2 in the cytoplasm and
nucleus compared with the corresponding control cells (Fig. 4, J–L). Furthermore,
we detected marked reduction of ANXA1 protein and its receptor after
gold particles conjugated with ANXA1 and FPR2/ALX in mast cells (G–I) and neutrophils (J–L). Data are expressed as the mean¡ SEM of colloidal gold
particles per mm in the plasma membrane and per mm2 in the cytoplasm and nucleus of cells (n510 cells per group). One-way ANOVA followed by
Bonferroni’s test revealed a significant difference among the groups. * P,0.05, ** P,0.01, *** P,0.001 vs. control, ## P,0.01, ### P,0.001 vs.
peritumoral. Stained with uranyl acetate and lead citrate. Scale bars: 1 mm.
doi:10.1371/journal.pone.0111317.g002
Role of the ANXA1/FPR2 Interaction in Larynx Cancer
PLOS ONE | DOI:10.1371/journal.pone.0111317 December 9, 2014 11 / 23
ANXA12–26+Boc2 treatment compared with ANXA12–26-treated cells (Fig. 4, J–L).
Treatment with ANXA12–26 significantly augmented the degree of ANXA1/FPR2
co-localization in the plasma membrane of Hep-2 cells (Fig. 4 J).
Decreased Pro-inflammatory Cytokine Levels Characterizes the
Anti-inflammatory Effect of ANXA1 on Laryngeal Cancer Cells
The expression pattern of IL-6, IL-8 and MCP-1 was similar among the
experimental conditions (Fig. 5, A–C). The Hep-2 cells that were incubated with
ANXA12–26, ANXA12–26+Boc2, Dexa and Dexa+Boc2 showed a marked reduction
in cytokine levels. However, the Boc2-treated cells showed a high level of cytokine
expression that was similar to that observed under control conditions (Fig. 5, A–
C).
EP3- and EP4-Mediated Metalloproteinase Signaling Can Be
Regulated by ANXA12–26 in Tumor Cells
To investigate the possible effect of ANXA1 on the expression of genes that are
involved in the prostaglandin pathway and, therefore, are related to tumorigenesis
and inflammation, we carried out real time PCR in Hep-2 cells that were
incubated with ANXA12–26 and Boc2. Prior to RT-PCR, we evaluated the quality
of mRNA and cDNA obtained from the samples (S3 Figure, A and B).
Fig. 3. Effect of the peptide ANXA12–26 and antagonist Boc2 on the proliferation of Hep-2 cells.
Treatment with ANXA12–26 reduced the cellular growth. The antagonist Boc2 partially inhibited the anti-
proliferative effect of ANXA12–26. The cells treated with Boc2 alone showed a level of proliferation similar to
that of the control. The Hep-2 cells were seeded in MEM-Earle medium at a density of 26106 cells in 75-cm2
culture flask, and then were incubated with serum-free medium 24 hours prior to the addition of ANXA12–26
(1 mM), ANXA12–26 (1 mM)+Boc (10 mM) or Boc (10 mM) alone. All of the experiments were performed in
triplicate to confirm the results. Data are expressed as the mean¡ SEM of the cell number6106. ** P,0.01
and *** P,0.001 vs. control, ## P,0.01 and ### P,0.001 vs. ANXA12–26+Boc.
doi:10.1371/journal.pone.0111317.g003
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Fig. 4. Ultrastructural immunocytochemistry detection of ANXA1 and FPR2/ALX co-localization in laryngeal cells by electron microscopy.
Immunolabeling with 10-nm (FPR2/ALX) and 15-nm (ANXA1) colloidal gold particles. (A–C) Epithelial control, peritumoral and tumor cells from laryngeal
tissues. (D–E) Hep-2 cells showing immunoreactivity to ANXA1 (arrows), FPR2 (arrowheads), and co-localizations (curve arrows) in the plasma membrane,
cytoplasm and nucleus (N). Desmosomes (open curve arrows) are detected between these cells. (F) The absence of immunoreactivity to ANXA1 and FPR2/
ALX in cells incubated with nonimmune serum. Density of gold particles conjugated with ANXA1 and FPR2/ALX in epithelial cells (G–I) and Hep-2 cells (J–
L). Hep-2 cells were seeded in MEM-Earle medium at a density of 26106 cells in 75-cm2 culture flasks, and then were incubated with serum-free medium
24 hours prior to the addition of ANXA12–26 (1 mM) and ANXA12–26 (1 mM)+Boc2 (10 mM). Data are expressed as the mean ¡ SEM of colloidal gold
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Hep-2 cells that were treated with ANXA12–26 showed a significant decrease
(Log2#21.0) in MMP2 expression and an increase (Log2$1.0) in MMP9
expression compared with control cells (Fig. 6). However, incubation of Hep-2
cells with ANXA12–26 plus Boc mediated up-regulation (Log2$1.0) of EP4,
MMP2 and MMP9 gene expression and down-regulation (Log2#21.0) of EP3
expression compared with control cells (Fig. 6).
Discussion
Although advances in new diagnostic tools and treatments have led to declining
mortality rates, cancer remains a leading cause of death in industrialized
countries. A better understanding of the interactions between tumors and
inflammation may lead to new biological targets for therapeutic intervention in
particles per mm in the plasma membrane and per mm2 in the cytoplasm and nucleus of cells (n510 cells per group). One-way ANOVA followed by
Bonferroni’s test revealed a significant difference among the groups. * P,0.05, ** P,0.01, *** P,0.001 vs. control,# P,0.05,## P,0.01, ### P,0.001
vs. ANXA12–26. Stained with uranyl acetate and lead citrate. Scale bars: 1 mm.
doi:10.1371/journal.pone.0111317.g004
Fig. 5. Effect of the peptide ANXA12–26 on proinflammatory cytokine expression. Low expression of IL-6
(A), IL-8 (B) and MCP-1 (C) after treatment with ANXA12–26 and dexamethasone. Hep-2 cells were seeded in
MEM-Earle medium at a density of 26106 cells in 75-cm2 culture flasks, and then were incubated with serum-
free medium 24 hours prior to the addition of ANXA12–26 (1 mM), ANXA12–26 (1 mM)+Boc2 (10 mM), Dexa
(0.01 mM), Dexa (0.01 mM)+Boc2 (10 mM) or Boc2 (10 mM) alone. All of the experiments were performed in
triplicate to confirm the results. Data are expressed as the mean¡ SEM of the analyte concentration (pg/mL),
determined using MAGPIX xPONENT software. * P,0.05, ** P,0.01 and *** P,0.001 vs. control, ##
P,0.01 and ### P,0.001 vs. ANXA12–26, 11 P,0.01 and 111 P,0.001 vs. ANXA12–26+Boc2.
doi:10.1371/journal.pone.0111317.g005
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different neoplasms within the context of chronic inflammation, such as laryngeal
carcinoma. We showed that ANXA1 protein may control tumor growth in a
paracrine manner that is mediated by the receptor FPR2/ALX. In the
inflammatory cells of human laryngeal carcinoma tissue samples, ANXA1/FPR2
expression was markedly exacerbated; however, in laryngeal carcinoma cells, this
expression was down-regulated. Treatment with ANXA12–26 reduced the
proliferation of Hep-2 cells and up-regulated ANXA1/FPR2 expression in these
cells. Our results established, for the first time, the role of FPR2/ALX in laryngeal
carcinoma cells as demonstrated by ultrastructural analyses showing the co-
localization of ANXA1/FPR2.
The inflammatory components in a developing neoplasm may include several
types of immune cells, including mast cells and neutrophils, which can produce an
array of cytokines, such as the cell-killing mediators TNF-a and interleukins (ILs)
[48, 49]. The presence of degranulated mast cells in the peritumoral and tumor
laryngeal tissues suggests that neoplastic cells may recruit and activate mast cells to
release mediators that could either be detrimental to the tumor or contribute to its
development [50]. Intriguingly, most reports show the localization of mast cells
predominantly at the tumor periphery [51] and associated with the vasculature
surrounding malignant tissues, suggesting that these cells play a pro-angiogenic
role [52]. The scarcity of mast cells within the tumor core may be a histology
artifact that results from mast cell degranulation, leading to ‘‘ghosts’’ following
staining [53]. Our data indicate that mast cells may represent a possible target for
therapeutic intervention in controlling tumor growth and angiogenesis in
laryngeal carcinoma.
Fig. 6. Gene expression in Hep-2 cells using real-time PCR. (A) Down- and up-regulated expression of
MMP2 and MMP9, respectively, after ANXA12–26 treatment. (B) Overexpression of EP4, MMP2 and MMP9,
and down-regulation of EP3 after ANXA12–26+Boc. Hep-2 cells were seeded in MEM-Earle medium at a
density of 26106 cells in 75-cm2 culture flasks, and then were incubated with serum-free medium, 24 hours
prior to the addition of ANXA12–26 (1 mM) and ANXA12–26 (1 mM)+Boc2 (10 mM). All of the experiments are
representative of three separate experiments. GAPDH was used as the internal reference and the control
sample was used as the calibrator. Values were Log2 transformed (y-axis) so that all values below 21
indicated down-regulation in gene expression while values above 1 represented up-regulation compared with
control cells.
doi:10.1371/journal.pone.0111317.g006
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Mast cells may be effective in inducing neutrophil migration to inflammatory
sites [54], numerous transmigrated neutrophils were observed in the larynx tumor
samples. Despite their known function as phagocytes, the role of tumor-associated
neutrophils in neoplastic progression has been controversial [19, 55]. Neutrophils
can induce DNA damage in proliferating cells through the generation of reactive
oxygen and nitrogen species, which are normally produced by these cells to fight
infection [55]. However, neutrophils can have both tumor-promoting and
tumoricidal functions, depending on the presence of TGF-b [20]. The recognition
of neutrophils as a key component of tumor growth opens an avenue for novel
approaches to cancer therapies to decrease laryngeal carcinoma cell proliferation
and metastasis in patients.
It is now evident that inflammatory cells have powerful effects on tumor
development. Early in the neoplastic process, these cells are malignant promoters,
producing an attractive environment for tumor growth, facilitating genomic
instability and promoting angiogenesis [21]. Inflammatory cells can regulate the
growth, migration and differentiation of all cell types in the tumor microenvir-
onment [49]. Thus, it is clear that anti-inflammatory therapy is efficacious toward
preventing early neoplastic progression.
In this anti-inflammatory and anti-proliferative study, we have unveiled
whether ANXA1 protein could be mediated by receptors for formylated peptides
(FPRs) in larynx cancer. The functions of FPRs in cancer are still not well
established.
We analyzed the role of ANXA1/FPR2 interactions in the proliferation of Hep-2
cells after treatment with ANXA12–26, dexamethasone and/or Boc2. The addition
of ANXA12–26 and Dexa to the cell culture reduced cell growth, showing the
antiproliferative effects of these anti-inflammatory drugs. However, the
pharmacological antagonist Boc2 attenuated the antiproliferative activity of
ANXA1, suggesting that this receptor plays central roles in the proliferation
response in larynx cancer. These data corroborate the results of a recent study
[56], which showed that the effects of ANXA1 on breast tumor cell proliferation
were prevented by Boc2.
To uncover the subcellular localization and possible interaction of ANXA1/
FPR2, we performed immunocytochemistry reactions in the inflammatory and
epithelial cells of laryngeal tissue samples and in Hep-2 cells. Co-localization of
ANXA1/FPR2 was detected in the mast cells, neutrophils, and tumor cells. These
data suggest that the anti-inflammatory/antiproliferative activity of ANXA1 may
be mediated by FPR2/ALX and show, for the first time, the presence of the
receptor FPR2/ALX and its interaction with ANXA1 in mast cells and laryngeal
tumor cells. Recently, we also detected the co-localization of ANXA1/Fpr2 in
murine neutrophils, suggesting that the anti-inflammatory ANXA1 effects may be
mediated through this receptor [57].
The mast cells and neutrophils in the peritumoral and tumor sections revealed
high expression of ANXA1/FPR2. The tumor-activated inflammatory cells appear
to increase the synthesis of ANXA1/FPR2 proteins as an anti-inflammatory
response mechanism to resolve the inflammation and proliferation in laryngeal
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cancer. The cellular differentiation and, in some cases, activation are stimuli for
the synthesis of ANXA1, although the molecular processes are not yet fully
understood [58].
Loss of ANXA1 and FPR2/ALX expression was detected in laryngeal carcinoma
cells. However, Hep-2 cells had up-regulated expression of ANXA1, FPR2/ALX
and co-localization after treatment with ANXA12–26 peptide. These results could
signify the regulatory role of the ANXA1/FPR2 interaction in cancer development
and, corroborate the previous investigation performed in our laboratory [32]
demonstrating that ANXA12–26-treated Hep-2 cells exhibited increased ANXA1
expression as shown by real time PCR. In vitro treatment with ANXA12–26+Boc2
markedly reduced the expression of ANXA1/FPR2 in Hep-2 cells. This result
confirms that the antagonist Boc2 blocks the antiproliferative FPR2-mediated
activity of ANXA1. Overexpression of ANXA1 protein is observed in
hepatocellular carcinoma [29] and pancreatic cancer [59]. By contrast, reduced
levels of ANXA1 protein expression have been reported in esophageal cancer [30]
and laryngeal cancer [32]. The discrepancy in these studies indicates that the
effects of ANXA1 on cancer cells may be cell-type specific and that factors other
than the expression level may affect its function.
The electron microscopy data demonstrated that ANXA1/FPR2 expression was
high in the cytoplasm and nucleus and low in the plasma membrane. ANXA1,
which is usually located in the cytoplasm, can translocate to the nucleus after
stimulation. Recently, Lin and colleagues [60] analyzed 115 patients with oral
carcinoma and observed high expression of ANXA1 in the nucleus of epithelial
tumor cells that correlated with poor prognosis. Although these authors [60] have
shown that ANXA1 translocation to the nucleus correlates with the regulation of
epithelial cell proliferation and may represent a candidate prognostic marker [43],
the precise physiological role of ANXA1 in the nucleus remains poorly
understood.
Because of the importance of cytokine control of the inflammatory
microenvironment favoring or inhibiting tumor progression [48, 61], we
investigated the level of IL-6, IL-8 and MCP-1 released by Hep-2 cells. IL-6 is
produced by tumor and stromal cells and contributes to tumorigenesis by various
mechanisms, including angiogenesis, cell survival and metastasis [62]. IL-6
signaling leads to the increased production of inflammatory cytokines, proteases
and growth factors, such as IL-1b, IL-8, MCP-1, MMP9, MMP2 and VEGF
[61, 63]. Our data showed that ANXA1 and dexamethasone inhibit the release of
inflammatory cytokines by Hep-2 cells, which may prevent the development of
laryngeal squamous cell carcinoma.
Additionally, we have begun to outline the anti-inflammatory pathway of
ANXA1 in Hep-2 cells which may result in the inhibition of angiogenic and
invasive phenotypes. Thus, we investigated the effect of ANXA1 on the expression
of genes that are involved in prostaglandin signaling and whose role in head and
neck cancer deserves evaluation [41]: EP3 and EP4 and their downstream effectors
MMP2 and MMP9. Prostaglandins are lipid mediators of inflammation released in
response to different stimuli, including cigarette smoking [64]. They are
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synthesized from arachidonic acid by cyclooxygenase (COX) in many cells, such
as mast cells, and exert their signaling effects through G-protein-coupled receptors
(reviewed by Aoki and Narumiya) [65].
Prostaglandin E2 is the most important COX metabolite present in human
tumors and that bind to its receptors (EP1–4) on the plasma membrane of
neoplastic, stromal or immune cells. The EP receptors may have distinct functions
depending on the cell and tissue type [66]. For example, EP4 is linked to cAMP/
PKA and PI3K/Akt pathways whereas the multiple isoforms of EP3 may negatively
or positively regulate cAMP [67]. They can transactivate the epidermal growth
factor receptor (EGFR), a biomarker that is virtually upregulated in all head and
neck tumors, inducing the expression of several proteins, including COX 2, matrix
metalloproteinases 2 and 9 and vascular endothelial growth factor [68].
Otherwise, EP signaling may stimulate EGFR ligand release via matrix
metalloproteinases [69]. These molecular signaling cascades promote tumor cell
proliferation, angiogenesis and extracellular matrix degradation and may be
targets for the treatment and prevention of cancer. Indeed, several epidemiological
studies have shown an inverse correlation between cancer risk and non-steroidal
anti-inflammatory drugs, which are potent inhibitors of cyclooxygenase (COX)
[68]. Treatment of Hep-2 cells with ANXA12–26 reduced MMP2 expression and
increased MMP9 expression. Unexpectedly, up-regulation of EP4, MMP2 and
MMP9 and down-regulation of EP3 expression were observed after treatment with
ANXA12–26 and Boc2. Te latter findings show that ANXA1 may affect the
expression of MMPs and EP receptors through its interaction with the receptor
FPR2/ALX. Therefore, may interact with different receptors, generating signals
that are interconnected with the prostaglandin pathway. Clearly, further
investigation is needed.
Overall, our in vivo data indicated that mast cells and neutrophils, under
activation by the tumor microenvironment, demonstrate up-regulation of
ANXA1/FPR2 as an anti-inflammatory response mechanism to resolve inflam-
mation and proliferation in laryngeal cancer. However, in vitro results have
indicated that treatment with the peptide mimetic ANXA12–26 promotes the
reduction of Hep-2 cell proliferation, up-regulation of ANXA1/FPR2 expression,
down-regulation of inflammatory cytokines (IL-6, IL-8 and MCP-1) and MMP2.
Conclusions
Integration of the in vivo and in vitro data showed that ANXA1 may be effective
in the regulation of tumor growth and metastasis through paracrine mechanisms
mediated by FPR2/ALX. Detailed studies of mast cell and neutrophil function in
different types of cancer should aid the development of effective antitumor
strategies. In light of the potential importance ascribed to ANXA1, our study not
only has generated novel and important information about ANXA1 mechanisms
but also may justify further investigation of the roles of the complex FPR receptor
family. In addition, a combination of anti-inflammatory approaches that target
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the tumor microenvironment with more sophisticated and selective tumoricidal
drugs may lead to future therapeutic intervention in human laryngeal cancer.
Supporting Information
S1 Figure. Analysis of Hep-2 cell viability. Treatment with ANXA12–26, ANXA12–
26+Boc2, Dexa, Dexa+Boc2 or Boc2 did not affect the percentage of cellular
viability during growth curve analysis. The Hep-2 cells were seeded in MEM-Earle
medium at a density of 26106 cells in 75-cm2 culture flasks, and then were
incubated with serum-free medium, 24 hours prior to the addition of ANXA12–26
(1 mM), ANXA12–26 (1 mM)+Boc2 (10 mM), Dexa (0.01 mM), Dexa
(0.01 mM)+Boc2 (10 mM) or Boc2 (10 mM) alone. All experiments were
performed in triplicate to confirm the results. Data are expressed as the mean ¡
SEM of the cell percentage number.
doi:10.1371/journal.pone.0111317.s001 (TIF)
S2 Figure. Effect of dexamethasone on the proliferation of Hep-2 cells. Treatment
with dexamethasone (Dexa) reduced the cellular growth. The antagonist Boc2 had
no effect on Dexa. Hep-2 cells were seeded in MEM-Earle medium at a density of
26106 cells in 75-cm2 culture flasks, and then were incubated with serum-free
medium, 24 hours prior to the addition of Dexa (0.01 mM) and Dexa
(0.01 mM)+Boc2 (10 mM). All of the experiments were performed in triplicate to
confirm the results. Data are expressed as the mean ¡ SEM of the cell number
6106. ** P,0.01, *** P,0.001 vs. control.
doi:10.1371/journal.pone.0111317.s002 (TIF)
S3 Figure. Validation of mRNA and cDNA integrity. Agarose gels showing the
quality of mRNA (A) and cDNA (B) from Hep-2 cells after treatment. Hep-2 cells
were seeded in MEM-Earle medium at a density of 26106 cells in 75-cm2 culture
flasks, and then were incubated with serum-free medium, 24 hours prior to the
addition of ANXA12–26 (1 mM) and ANXA12–26 (1 mM)+Boc2 (10 mM). All of the
experiments were performed in triplicate to confirm the results.
doi:10.1371/journal.pone.0111317.s003 (TIF)
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